Nakashima L - Search Results

1

Barriers and facilitators for the safe handling of antineoplastic drugs.

Fazel SS, Keefe A, Shareef A, Palmer AL, Brenner DR, Nakashima L, Koehoorn MW, McLeod CB, Hall AL, Peters CE. Fazel SS, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2022 Dec;28(8):1709-1721. doi: 10.1177/10781552211040176. Epub 2021 Oct 6. J Oncol Pharm Pract. 2022. PMID: 34612752 Review.

2

A real-world data approach to determine the optimal dosing strategy for pembrolizumab.

Jang A, Nakashima L, Ng T, Fung M, Jiwani S, Schaff K, Suess J, Goncalves R, Jang D, Kuik K, Labelle S, Pow A. Jang A, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2021 Apr;27(3):635-643. doi: 10.1177/1078155220929756. Epub 2020 Jun 15. J Oncol Pharm Pract. 2021. PMID: 32539663 Clinical Trial.

3

Real-world incidence of venetoclax toxicities in British Columbia.

Lee C, Markarian A, Ladha F, Nakashima L, de Lemos M, Schaff K, Woo S, Gerrie A. Lee C, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2022 Jul;28(5):1163-1169. doi: 10.1177/10781552221084616. Epub 2022 Mar 7. J Oncol Pharm Pract. 2022. PMID: 35253497

4

Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.

Truong J, Yeung SST, Kletas V, de Lemos M, Schaff K, Nakashima L. Truong J, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2023 Sep 1:10781552231199048. doi: 10.1177/10781552231199048. Online ahead of print. J Oncol Pharm Pract. 2023. PMID: 37654194

5

Occupational Exposure to Antineoplastic Drugs: Identification of Job Categories Potentially Exposed throughout the Hospital Medication System.

Hon CY, Teschke K, Chua P, Venners S, Nakashima L. Hon CY, et al. Among authors: nakashima l. Saf Health Work. 2011 Sep;2(3):273-81. doi: 10.5491/SHAW.2011.2.3.273. Epub 2011 Sep 30. Saf Health Work. 2011. PMID: 22953211 Free PMC article.

6

International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.

Walker A, Chan A, Labra CC, de Lemos ML, Geirnaert M, Albert-Marí MA, Atik EA, Borlagdan J, Crespo A, Danilak M, Kandemir EA, Lim C, Alabelewe RM, Mutiara R, Tewthanom K, Yim B, Nakashima L. Walker A, et al. Among authors: nakashima l. J Oncol Pharm Pract. 2023 Jul;29(5):1065-1074. doi: 10.1177/10781552221090199. Epub 2022 Apr 5. J Oncol Pharm Pract. 2023. PMID: 35382638

7

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.

Gelmon KA, O'Reilly SE, Tolcher AW, Campbell C, Bryce C, Ragaz J, Coppin C, Plenderleith IH, Ayers D, McDermott B, Nakashima L, Healey D, Onetto N. Gelmon KA, et al. Among authors: nakashima l. J Clin Oncol. 1996 Apr;14(4):1185-91. doi: 10.1200/JCO.1996.14.4.1185. J Clin Oncol. 1996. PMID: 8648373 Clinical Trial.

8

Evolution of cancer treatment and evolving challenges.

Nakashima L. Nakashima L. Healthc Manage Forum. 2018 Jan;31(1):26-28. doi: 10.1177/0840470417722568. Healthc Manage Forum. 2018. PMID: 29264971 Review.

9

Treatment of Kawasaki disease.

Nakashima L, Edwards DL. Nakashima L, et al. Clin Pharm. 1990 Oct;9(10):755-62. Clin Pharm. 1990. PMID: 2242655 Review.

10

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

Gelmon KA, Tolcher A, O'Reilly S, Campbell C, Bryce C, Shenkier T, Ragaz J, Ayers D, Nakashima L, Rielly S, Dulude H. Gelmon KA, et al. Among authors: nakashima l. Ann Oncol. 1998 Nov;9(11):1247-9. doi: 10.1023/a:1008445123416. Ann Oncol. 1998. PMID: 9862057 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page